Report of safety of the use of a short 32g needle for intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity

Linda A. Cernichiaro-Espinosa, Clio A. Harper, Sarah P. Read, Lauren M. Wright, Frank W. Scribbick, Ryan Young, Catherin I. Negron, Ana Rodríguez, Audina M. Berrocal

Research output: Contribution to journalArticle

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)1251-1255
Number of pages5
JournalRetina
Volume38
Issue number6
DOIs
StatePublished - Jun 1 2018

Keywords

  • anti-VEGF
  • antiangiogenic
  • bevacizumab
  • children
  • intravitreal injection
  • prematurity
  • ranibizumab
  • retinopathy of prematurity
  • short needle
  • technique

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Cernichiaro-Espinosa, L. A., Harper, C. A., Read, S. P., Wright, L. M., Scribbick, F. W., Young, R., Negron, C. I., Rodríguez, A., & Berrocal, A. M. (2018). Report of safety of the use of a short 32g needle for intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity. Retina, 38(6), 1251-1255. https://doi.org/10.1097/IAE.0000000000002172